Sales Up 10%At Synthelabo
French drugmaker Synthelabo has announced sales growth in the first six months of 1996 of 10.2% to 5.1 billion French francs ($1 billion). The company said that pharmaceutical sales advanced 10.8% on a comparable basis in the first half to 4.7 billion francs. Good results abroad were said to be the driver.
Sales of the firm's seven strategic products (Marketletters passim) grew 1% due to fine performances from the hypnotic Stilnox (zolpidem), the anxiolytic Xatral (alfuzosin) and Solian (amisulpride). The antiulcerant Inipomp (pantoprazole) was successfully launched in France in March.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze